JP2006515339A5 - - Google Patents

Download PDF

Info

Publication number
JP2006515339A5
JP2006515339A5 JP2006500034A JP2006500034A JP2006515339A5 JP 2006515339 A5 JP2006515339 A5 JP 2006515339A5 JP 2006500034 A JP2006500034 A JP 2006500034A JP 2006500034 A JP2006500034 A JP 2006500034A JP 2006515339 A5 JP2006515339 A5 JP 2006515339A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
group
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006500034A
Other languages
English (en)
Japanese (ja)
Other versions
JP4608480B2 (ja
JP2006515339A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/001477 external-priority patent/WO2004074257A1/en
Publication of JP2006515339A publication Critical patent/JP2006515339A/ja
Publication of JP2006515339A5 publication Critical patent/JP2006515339A5/ja
Application granted granted Critical
Publication of JP4608480B2 publication Critical patent/JP4608480B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006500034A 2003-02-18 2004-02-17 非ヌクレオシド逆転写酵素インヒビター Expired - Fee Related JP4608480B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44797403P 2003-02-18 2003-02-18
PCT/EP2004/001477 WO2004074257A1 (en) 2003-02-18 2004-02-17 Non-nucleoside reverse transcriptase inhibitors

Publications (3)

Publication Number Publication Date
JP2006515339A JP2006515339A (ja) 2006-05-25
JP2006515339A5 true JP2006515339A5 (enExample) 2009-12-10
JP4608480B2 JP4608480B2 (ja) 2011-01-12

Family

ID=32908518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006500034A Expired - Fee Related JP4608480B2 (ja) 2003-02-18 2004-02-17 非ヌクレオシド逆転写酵素インヒビター

Country Status (17)

Country Link
US (1) US7241794B2 (enExample)
EP (1) EP1597235B1 (enExample)
JP (1) JP4608480B2 (enExample)
KR (1) KR100776093B1 (enExample)
CN (1) CN100389109C (enExample)
AR (1) AR043195A1 (enExample)
AT (1) ATE370124T1 (enExample)
BR (1) BRPI0407591A (enExample)
CA (1) CA2515151C (enExample)
CL (1) CL2004000270A1 (enExample)
DE (1) DE602004008227T2 (enExample)
ES (1) ES2291854T3 (enExample)
MX (1) MXPA05008748A (enExample)
PL (1) PL378556A1 (enExample)
RU (1) RU2305680C2 (enExample)
TW (1) TW200423930A (enExample)
WO (1) WO2004074257A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524397A1 (en) * 2003-05-07 2004-11-18 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
JP4993407B2 (ja) 2004-08-04 2012-08-08 大正製薬株式会社 トリアゾール誘導体
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
PL1988083T3 (pl) 2006-02-03 2014-08-29 Taisho Pharmaceutical Co Ltd Pochodna triazolowa
RU2395499C2 (ru) 2006-02-06 2010-07-27 Тайсо Фармасьютикал Ко., Лтд. Ингибитор связывания сфингозин-1-фосфата
KR101401139B1 (ko) * 2006-02-14 2014-05-29 이하라케미칼 고교가부시키가이샤 5-알콕시-4-히드록시메틸피라졸 화합물의 제조방법
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
DE602007013573D1 (de) * 2006-08-16 2011-05-12 Hoffmann La Roche Nicht-nukleosidische reverse-transkriptase-hemmer
MX2009009920A (es) 2007-03-29 2009-10-19 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
ATE554070T1 (de) 2007-08-01 2012-05-15 Taisho Pharmaceutical Co Ltd Hemmer der s1p1-bindung
AU2008340422B2 (en) * 2007-12-21 2014-06-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
DE102008015033A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
MX2012011379A (es) * 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
ES2565193T3 (es) 2010-07-15 2016-04-01 Sumitomo Dainippon Pharma Co., Ltd. Compuesto de pirazol
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CA2876969A1 (en) 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
BR112014031896A2 (pt) 2012-06-20 2017-06-27 Univ Vanderbilt composto, composição farmacêutica, e, método para o tratamento de um distúrbio
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
AU2014315151A1 (en) 2013-09-06 2016-03-03 Inception 2, Inc. Triazolone compounds and uses thereof
SI3125894T1 (sl) 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
US20180042234A1 (en) * 2015-03-19 2018-02-15 E I Du Pont De Nemours And Company Fungicidal pyrazoles
US20200002283A1 (en) * 2016-06-29 2020-01-02 Esteve Pharmaceuticals, S.A. Pyrazole derivatives having activity against pain
CN110818636A (zh) * 2019-11-29 2020-02-21 河北科技大学 一种化合物或其盐及其应用和合成方法
CN115677585B (zh) * 2022-10-31 2024-03-19 上海群力化工有限公司 一种甲醛吡唑衍生物的合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9509024A (pt) 1994-09-26 1997-09-30 Shionogi & Co Derivados de imidazol
DE19734664A1 (de) * 1997-08-11 1999-02-18 Bayer Ag (Hetero)Aryloxypyrazole
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
GB0028484D0 (en) * 2000-11-22 2001-01-10 Hoffmann La Roche Imidazolone derivatives for the treatment of viral diseases
SI1762567T1 (sl) * 2001-04-10 2012-08-31 Pfizer Derivati pirazola za zdravljenje HIV-a
GB0113524D0 (en) * 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives

Similar Documents

Publication Publication Date Title
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2021534124A5 (enExample)
JP2005514366A5 (enExample)
RU2007119562A (ru) Тетрациклические производные индолов в качестве противовирусных агентов
JP2005501120A5 (enExample)
JP2007517044A5 (enExample)
JP2008514732A5 (enExample)
RU2004132203A (ru) Индолилмалеимидные производные
RU2005128832A (ru) Ненуклеозидные ингибиторы ревертазы
NO20045103L (no) Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse
RU2003115429A (ru) Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
JP2006507326A5 (enExample)
RU2006134020A (ru) Конденсированные производные пиразола
EP1353911A4 (en) ANTIVIRAL AGENTS
CA2295087A1 (en) Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
JP2011505347A5 (enExample)
JP2005527542A5 (enExample)
JP2005518357A5 (enExample)
RU2007108863A (ru) Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3
RU2004103475A (ru) Производные арил-или гетероарилазолилкарбинолов для лечения недержания мочи
JP2004525183A5 (enExample)
JP2005511594A5 (enExample)
JP2004521150A5 (enExample)
JP2024112835A5 (enExample)
UA81640C2 (ru) Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе